News

ERES Announces Upcoming Monthly Cash Distribution for 2025

ERES Announces Upcoming Monthly Cash Distribution for 2025

ERES Announces May 2025 Monthly Distribution

European Residential Real Estate Investment Trust (TSX: ERE.UN, “ERES”) is excited to share that the trustees have declared the May 2025 monthly cash distribution of €0.005 per Unit and Class B LP Unit, translating to an annualized rate of €0.06 per Unit. This distribution is set to benefit the Unitholders holding Units and Class B LP Units, which will be based on records as of May 30, 2025, with payments scheduled for June 16, 2025.

The distribution, denominated in Euros, will be converted and paid in Canadian dollars at the prevailing exchange rate on the payment date, with an estimated value of C$0.00774 per Unit and Class B LP Unit. Registered Unitholders have the opportunity to choose to receive this distribution in Euros instead of Canadian dollars. Should they not make such an election, distributions will automatically be converted to Canadian dollars as per the announced exchange rate. However, it’s important to note that beneficial Unitholders will not have this option available. For reference, the final distribution related to April 2025 stood at C$0.00774 per Unit and Class B LP Unit.

Commitment to Continuous Distributions

ERES remains dedicated to maintaining regular monthly distributions, contingent upon the Board of Trustees' discretion. ERES Limited Partnership will correspondingly distribute cash to holders of Class B LP Units, upholding their commitment to essential and stable returns for their investors.

Understanding ERES

ERES is an unincorporated, open-ended real estate investment trust that operates exclusively on the TSX with the symbol ERE.UN. It stands out as Canada’s sole European-focused multi-residential REIT, boasting a portfolio filled with high-quality multi-residential properties predominantly situated in the Netherlands. As of the latest reports, ERES owns 2,594 residential suites along with ancillary retail space in the Netherlands, additionally holding a commercial property in Germany and one in Belgium. The entire portfolio is valued at approximately €729.1 million.

Staying Informed About ERES

For those interested in learning more about ERES, its ongoing business ventures, and investment highlights, they can discover further information on the company’s website. It’s encouraged to visit their resources available under their SEDAR+ profile for comprehensive public disclosures.

Contact Information for Inquiries

ERES’s registered and main business office is located at 11 Church Street, Suite 401, Toronto, Ontario M5E 1W1. For additional inquiries or information, the following contacts are available:

Key Contacts

Mr. Mark Kenney
Chief Executive Officer
Phone: 416.861.9404
Email: m.kenney@capreit.net

Ms. Jenny Chou
Chief Financial Officer
Phone: 416.354.0188
Email: j.chou@capreit.net

Frequently Asked Questions

What is the May 2025 distribution amount announced by ERES?

The May 2025 distribution announced by ERES is €0.005 per Unit and Class B LP Unit, equivalent to €0.06 per Unit on an annualized basis.

When will the payment for the May distribution be made?

The payment for the May distribution will be processed on June 16, 2025.

Can Unitholders choose the currency for their distribution?

Yes, registered Unitholders can elect to receive their distribution in Euros rather than Canadian dollars. If no election is made, the payment will default to Canadian dollars.

What is the fair value of ERES's property portfolio?

As of the latest updates, ERES's property portfolio has a total fair value of approximately €729.1 million, including properties in the Netherlands, Germany, and Belgium.

How can one get more information about ERES?

More information about ERES and its investment highlights can be found on their official website and in their disclosures on SEDAR+.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 16

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering Futures: George Weiss Supports Say Yes Expansion

Updated Category News Views 222

Empowering Futures Through Education As a prominent philanthropist and former hedge fund manager, George Weiss continues to advocate for transformative education initiatives. His recent support for the expansion of the Say Yes Buffalo program into Niagara Falls is a testament to his lifelong commitment to ensuring that students have access to higher education and...

Continue Reading
Dierks Bentley Unveils ROW 94 Full Proof Bourbon Delight

Updated Category News Views 217

Introducing ROW 94 Full Proof Bourbon by Dierks Bentley The Full-Throttle, Already Gold Medal-Winner is ROW 94's Third Expression. Country music superstar Dierks Bentley is thrilled to launch the boldest and most authentic bourbon in the ROW 94 lineup, known as ROW 94 Full Proof. Available for $54.99 per 750ml, this exciting new release comes just a year after the...

Continue Reading
ReShape Lifesciences Implements 1-for-58 Stock Consolidation Strategy

Updated Category News Views 61

ReShape Lifesciences Announces 1-for-58 Stock Consolidation Strategy In an effort to strengthen its presence in the market, ReShape Lifesciences Inc. (NASDAQ: RSLS), a frontrunner in weight loss and metabolic health solutions, has revealed a 1-for-58 reverse stock split of its common shares. This move, which has been approved by the company’s Board of Directors, will go...

Continue Reading
Join the Movement: Protect Your Rights as an AMLX Investor

Updated Category News Views 87

Understanding Shareholder Rights As a shareholder of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), it’s imperative to be aware of your rights and the actions you can take to safeguard your interests. With the ever-evolving landscape of corporate governance, understanding the power of your voice becomes crucial. Immediate action is often necessary, as there may be limited...

Continue Reading
Troilus Gold Secures $35 Million for Project Advancement

Updated Category News Views 271

Troilus Gold Corp. Secures $35 Million Loan Facility Troilus Gold Corp. (TSX: TLG; OTCQX: CHXMF; FSE: CM5R) has successfully finalized a loan agreement, securing a principal amount of up to US$35 million, approximately CDN$49 million, to bolster its development efforts. This financial support is aimed at facilitating a variety of pre-development activities, including...

Continue Reading